Company Analysis
Sign in

Alnylam Pharmaceuticals, Inc. (ALNY)

Nasdaq: ALNY · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2002
Full chart Alerts Compare
Grade6.8
◀ Past 7.0● Present 7.0▶ Future 6.3
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

588 patents granted to the 5 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Alnylam Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
588
588 utility, 1976 to Dec 31, 2025
Granted in 2025
31
Against 27 in 2024 and 18 in 2023
Applications published
1,068
59 of them in 2025
Names they are printed under
5
its own name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals85
Biotechnology44
Organic fine chemistry18
Optics1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name5 counted
ALNYLAM PHARMACEUTICALS, INC. its own name
US, as the owner printed on each patent. 11 more under the same name are not counted (printed in GB)
441 granted
290 published
Alnylam Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
0 granted
474 published
Sirna Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent
145 granted
239 published
SIRNA THERAPEUTICS, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
64 published
Alnylam Europe AG a subsidiary
DE, as the owner printed on each patent. 1 more under the same name are not counted (printed in US)
2 granted
1 published
Names not counted (2)
Alnylam Europe AG
No country is printed for it. 0 granted and 2 published under it are not counted.
ALNYLAM PHARMACEUTICALS, INC.
No country is printed for it. 0 granted and 1 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 23, 202512,503,699Compositions and methods for silencing UGT1a1 gene expressionBiotechnologyALNYLAM PHARMACEUTICALS, INC.
Dec 16, 202512,497,613Modified oligonucleotidesBiotechnologyALNYLAM PHARMACEUTICALS, INC.
Dec 9, 202512,492,401Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofPharmaceuticalsALNYLAM PHARMACEUTICALS, INC.
Dec 2, 202512,486,512Solute carrier family member iRNA compositions and methods of use thereofBiotechnologyALNYLAM PHARMACEUTICALS, INC.
Dec 2, 202512,486,503Short interfering nucleic acid (siNA) compositionsBiotechnologySirna Therapeutics, Inc.
Nov 25, 202512,480,125Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereofPharmaceuticalsALNYLAM PHARMACEUTICALS, INC.
Nov 18, 202512,473,550Coagulation factor V (F5) iRNA compositions and methods of use thereofPharmaceuticalsALNYLAM PHARMACEUTICALS, INC.
Nov 11, 202512,467,051Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofPharmaceuticalsALNYLAM PHARMACEUTICALS, INC.
Nov 4, 202512,460,206PCSK9 iRNA compositions and methods of use thereofPharmaceuticalsALNYLAM PHARMACEUTICALS, INC.
Sep 16, 202512,416,006Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereofBiotechnologyALNYLAM PHARMACEUTICALS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 18, 20252025/0382324MONOMERS AND METHODS FOR SYNTHESIS OF MODIFIED OLIGONUCLEOTIDESOrganic fine chemistryALNYLAM PHARMACEUTICALS, INC.
Dec 11, 20252025/0376682COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETINPharmaceuticalsAlnylam Pharmaceuticals, Inc.
Nov 13, 20252025/0346906COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENEPharmaceuticalsAlnylam Pharmaceuticals, Inc.
Oct 23, 20252025/0325575SYNTHESIS OF 3 -RNA OLIGONUCLEOTIDESPharmaceuticalsALNYLAM PHARMACEUTICALS, INC.
Oct 9, 20252025/0312490SYSTEMIC DELIVERY OF MYOSTATIN SHORT INTERFERING NUCLEIC ACIDS (SINA) CONJUGATED TO A LIPOPHILIC MOIETYPharmaceuticalsSIRNA THERAPEUTICS, INC.
Oct 2, 20252025/030496717BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOFBiotechnologyAlnylam Pharmaceuticals, Inc.
Oct 2, 20252025/0304957SINGLE-STRANDED LOOP OLIGONUCLEOTIDESBiotechnologyAlnylam Pharmaceuticals, Inc.
Oct 2, 20252025/0304613AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE CONJUGATION APPROACHOrganic fine chemistryALNYLAM PHARMACEUTICALS, INC.
Sep 11, 20252025/0283079ACTIN-BINDING LIM PROTEIN 3 (ABLIM3) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOFBiotechnologyALNYLAM PHARMACEUTICALS, INC.
Sep 11, 20252025/0283071MODIFIED DOUBLE STRANDED OLIGONUCLEOTIDESBiotechnologyALNYLAM PHARMACEUTICALS, INC.
What it applied for, 2024 to 2025: Pharmaceuticals 77 · Biotechnology 61 · Organic fine chemistry 15 · Optics 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ALNY · research, not advice